OpenEvidence

OpenEvidence is an American artificial intelligence company headquartered in Miami, Florida, focused on transforming how healthcare providers access and apply medical knowledge. Its core business revolves around an AI-powered medical search engine and clinical decision support platform. The company's mission is to organize and expand the world's collective medical knowledge to help doctors save lives and improve patient care. [2, 3, 4, 6, 9, 15]

The company's primary offering is an AI copilot for doctors that provides real-time, citation-linked answers synthesized exclusively from trusted, peer-reviewed medical literature. Key products and services include the DeepConsult feature, Coding Intelligence for billing, Doctor Dialer for telemedicine, and tools for clinical trials matching, patient handouts, and prior authorization letters. OpenEvidence serves verified U.S. clinicians, including physicians, nurses, and other healthcare professionals, and its platform is actively used across more than 10,000 hospitals and medical centers nationwide. [1, 4, 8, 9, 18, 19, 22, 25, 28]

OpenEvidence has rapidly grown to become the most widely used medical AI among verified U.S. clinicians and the fastest-growing clinical decision support platform in the United States. As of January 2026, the privately held company was valued at $12 billion following a $250 million Series D funding round, bringing its total funding to approximately $700 million. Co-founder and CEO Daniel Nadler was recognized on the TIME100 Health list in 2025. In April 2026, OpenEvidence withdrew its AI medical app from the EU and UK markets, citing regulatory uncertainty. The company has established numerous content licensing partnerships with leading medical organizations and journals, including The New England Journal of Medicine, JAMA Network, National Comprehensive Cancer Network (NCCN), and the American Urological Association (AUA). [1, 2, 3, 4, 5, 6, 8, 9, 12, 13, 14, 16, 17, 21, 24, 26]

Latest updates

AUA Partners with OpenEvidence to Embed Guidelines in AI Clinical Tools

Event summary

  • The American Urological Association (AUA) and OpenEvidence have entered a multi-year collaboration.
  • The agreement will integrate AUA Clinical Practice Guidelines and Clinical Consensus Statements into the OpenEvidence AI-powered clinical decision support platform.
  • OpenEvidence is the most widely used medical AI platform among U.S. physicians, serving hundreds of thousands of verified clinicians.
  • The AUA, founded in 1902, has over 25,000 members globally.
  • Lane Palmer, MD, President of the AUA, emphasized a proactive approach to shaping AI's role in clinical decision-making.

The big picture

The partnership reflects a broader shift towards proactive engagement by medical societies in the development and deployment of AI-driven clinical tools. This move positions the AUA to influence the evolution of AI in urology and potentially generate new revenue streams through data insights and expanded platform usage. The collaboration also highlights the increasing importance of evidence-based guidance in the age of AI, as clinicians seek reliable and authoritative information at the point of care.

What we're watching

Data Visibility
The AUA's acquisition of usage and gap analysis data from OpenEvidence will be critical; the quality and granularity of this data will determine the AUA's ability to refine future guidelines and influence adoption.
Competitive Landscape
How other medical societies respond to this trend of integrating guidelines into AI platforms will shape the future of clinical decision support and potentially create a fragmented or standardized ecosystem.
Guideline Integrity
The AUA must actively monitor how its guidelines are interpreted and applied within the OpenEvidence platform to ensure accuracy and prevent misrepresentation, safeguarding its reputation as a trusted source.

OpenEvidence Integrates NCCN Guidelines, Bolstering Oncology AI Platform

Event summary

  • OpenEvidence has integrated the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) into its AI platform.
  • The collaboration marks the beginning of a series of oncology-focused updates for OpenEvidence.
  • The integration provides clinicians with direct links to NCCN Guidelines and contextualizes guidance within broader clinical evidence.
  • Travis Zack, MD, PhD, Chief Medical Officer at OpenEvidence, and Samyukta Mullangi, MD, Vice President at OpenEvidence, both highlighted the value of the integration.

The big picture

The integration of NCCN Guidelines into OpenEvidence’s platform reflects a broader trend toward incorporating evidence-based clinical guidelines into AI-powered decision support systems. This move strengthens OpenEvidence’s position as a key player in the rapidly growing medical AI market, which is increasingly vital for managing the complexity and cost of cancer care. The collaboration also underscores the increasing importance of structured data and algorithmic transparency in clinical practice.

What we're watching

Adoption Rate
The success of this integration hinges on adoption by oncologists; slow uptake could limit OpenEvidence’s ability to expand its market share within the oncology space.
Content Accuracy
Maintaining the accuracy and timeliness of the integrated NCCN Guidelines will be crucial, as any discrepancies could erode clinician trust and expose OpenEvidence to liability.
Competitive Response
Other medical AI platforms are likely to respond with similar integrations, potentially intensifying competition and requiring OpenEvidence to continually innovate to maintain its lead.
CID: 1289